CL2015000418A1 - Formulacion acuosa topica que comprende un farmaco antiangiogenico que es un anticuerpo anti-vegf y un liposoma formado de un lipido a base de peg; su uso en el tratamiento de una enfermedad o condicion relacionada con vegf; y metodo para tratar cancer, psoriasis y edema macular diabetico, entre otras enfermedades. - Google Patents

Formulacion acuosa topica que comprende un farmaco antiangiogenico que es un anticuerpo anti-vegf y un liposoma formado de un lipido a base de peg; su uso en el tratamiento de una enfermedad o condicion relacionada con vegf; y metodo para tratar cancer, psoriasis y edema macular diabetico, entre otras enfermedades.

Info

Publication number: CL2015000418A1
Authority: CL; Chile
Prior art keywords: vegf; psoriasis; peg; diseases; disease
Prior art date: 2012-08-21

Application number

CL2015000418A

Other languages

English (en)

Inventor

Arturo Santos

Phillip Frost

Original Assignee

Opko Pharmaceuticals Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-08-21

Filing date

2015-02-20

Publication date

2015-07-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50150466&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015000418(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-02-20 Application filed by Opko Pharmaceuticals Llc filed Critical Opko Pharmaceuticals Llc

2015-07-10 Publication of CL2015000418A1 publication Critical patent/CL2015000418A1/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'

CL2015000418A 2012-08-21 2015-02-20 Formulacion acuosa topica que comprende un farmaco antiangiogenico que es un anticuerpo anti-vegf y un liposoma formado de un lipido a base de peg; su uso en el tratamiento de una enfermedad o condicion relacionada con vegf; y metodo para tratar cancer, psoriasis y edema macular diabetico, entre otras enfermedades. CL2015000418A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201261691455P	2012-08-21	2012-08-21
US201361791693P	2013-03-15	2013-03-15
US201361862300P	2013-08-05	2013-08-05

Publications (1)

Publication Number	Publication Date
CL2015000418A1 true CL2015000418A1 (es)	2015-07-10

Family

ID=50150466

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2015000418A CL2015000418A1 (es)	2012-08-21	2015-02-20	Formulacion acuosa topica que comprende un farmaco antiangiogenico que es un anticuerpo anti-vegf y un liposoma formado de un lipido a base de peg; su uso en el tratamiento de una enfermedad o condicion relacionada con vegf; y metodo para tratar cancer, psoriasis y edema macular diabetico, entre otras enfermedades.

Country Status (16)

Country	Link
US (2)	US10548841B2 (es)
EP (1)	EP2887958B1 (es)
JP (3)	JP6336448B2 (es)
KR (2)	KR102083700B1 (es)
CN (1)	CN104582728A (es)
AR (1)	AR092372A1 (es)
BR (1)	BR112015003658B1 (es)
CA (2)	CA3098856C (es)
CL (1)	CL2015000418A1 (es)
ES (1)	ES2881671T3 (es)
HU (1)	HUE058912T2 (es)
MX (2)	MX363822B (es)
PL (1)	PL2887958T3 (es)
RU (1)	RU2680096C2 (es)
TW (2)	TWI608848B (es)
WO (1)	WO2014031429A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160159893A1 (en) *	2013-07-11	2016-06-09	Gabriela Burian	Use of a VEGF Antagonist in Treating Retinopathy of Prematurity
JP6539661B2 (ja) *	2013-12-19	2019-07-03	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	眼疾患の処置において使用するためのｃｅｔｐモデュレーター
US20170056469A1 (en) *	2014-05-02	2017-03-02	Mayo Foundation For Medical Education And Research	Individualized treatment of eye disease
KR101778004B1 (ko)	2015-06-22	2017-09-15	(주) 에빅스젠	이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
TW201720446A (zh) *	2015-11-13	2017-06-16	Ｏｈｒ製藥公司	非典型脈絡膜新生血管（ｃｎｖ）之大小做為以角鯊胺治療之預測子
KR20210096592A (ko) *	2018-08-23	2021-08-05	번스타인, 에릭, 에프	피부 질환을 치료하기 위해 항-vegf 화합물을 도포하고 이러한 화합물을 이용하기 위한 시스템, 장치, 및 방법
CN109180798B (zh) *	2018-09-04	2020-10-27	武汉原生药谷生物医药科技有限公司	一种增强型治疗性抗体及其应用
CN113966237A (zh) *	2019-03-15	2022-01-21	罗德岛大学理事会	pHLIP®介导的皮质类固醇靶向病变组织
EP3968949A1 (en) *	2019-05-16	2022-03-23	OPKO Pharmaceuticals, LLC	Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations for prevention of macular thickening and its associated visual outcomes after lens surgery
CN113546172A (zh) *	2020-04-24	2021-10-26	山东大学齐鲁医院	Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用
US20230241080A1 (en) *	2020-06-15	2023-08-03	Arturo Santos	Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations as primary therapy for macular edema secondary to branch retinal vein occlusion
CN116585304B (zh) *	2023-04-25	2024-04-05	四川大学华西医院	一种急性肝损伤保护药物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6565861B1 (en) *	2000-02-11	2003-05-20	Isis Innovation Limited	Artificial tear formulation
US6610322B1 (en) *	2000-12-20	2003-08-26	Brian Charles Keller	Self forming, thermodynamically stable liposomes and their applications
US7785578B2 (en) *	2002-10-11	2010-08-31	Aciont, Inc.	Non-invasive ocular drug delivery
US20060165744A1 (en) *	2003-05-22	2006-07-27	Neopharm, Inc	Combination liposomal formulations
WO2007076274A2 (en) *	2005-12-22	2007-07-05	Bausch & Lomb Incorporated	Artificial tear solution containing poly (ethylene glycol) peg lipids
JP2009521510A (ja) *	2005-12-23	2009-06-04	アルコン，インコーポレイテッド	眼への受容体チロシンキナーゼ阻害（ｒｔｋｉ）化合物の送達のための医薬製剤
WO2008063932A2 (en) *	2006-11-10	2008-05-29	Genentech, Inc.	Method for treating age-related macular degeneration
KR101460816B1 (ko)	2006-12-07	2014-11-12	에프. 호프만-라 로슈 아게	포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
EP2212432A4 (en)	2007-10-22	2011-10-19	Schering Corp	COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
US8887944B2 (en) *	2007-12-11	2014-11-18	Tokitae Llc	Temperature-stabilized storage systems configured for storage and stabilization of modular units
CA2745832A1 (en) *	2008-12-04	2010-06-10	Opko Ophthalmics, Llc	Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
CN102665685A (zh)	2009-06-02	2012-09-12	念·吴	纯的peg-脂质缀合物
US20110033527A1 (en) *	2009-06-02	2011-02-10	Nian Wu	Opthalmic compositions of cyclosporin
US8956600B2 (en) *	2009-08-10	2015-02-17	Taiwan Liposome Co. Ltd.	Ophthalmic drug delivery system containing phospholipid and cholesterol
SG179085A1 (en) *	2009-09-09	2012-04-27	Avila Therapeutics Inc	Pi3 kinase inhibitors and uses thereof

2013
- 2013-08-15 KR KR1020157004549A patent/KR102083700B1/ko active IP Right Grant
- 2013-08-15 WO PCT/US2013/055084 patent/WO2014031429A2/en active Application Filing
- 2013-08-15 KR KR1020207005268A patent/KR102177437B1/ko active IP Right Grant
- 2013-08-15 US US14/422,587 patent/US10548841B2/en active Active
- 2013-08-15 EP EP13830622.0A patent/EP2887958B1/en active Active
- 2013-08-15 RU RU2015107317A patent/RU2680096C2/ru active
- 2013-08-15 ES ES13830622T patent/ES2881671T3/es active Active
- 2013-08-15 CN CN201380044348.4A patent/CN104582728A/zh active Pending
- 2013-08-15 HU HUE13830622A patent/HUE058912T2/hu unknown
- 2013-08-15 MX MX2015002233A patent/MX363822B/es active IP Right Grant
- 2013-08-15 CA CA3098856A patent/CA3098856C/en active Active
- 2013-08-15 CA CA2879597A patent/CA2879597C/en active Active
- 2013-08-15 BR BR112015003658-9A patent/BR112015003658B1/pt active IP Right Grant
- 2013-08-15 JP JP2015528536A patent/JP6336448B2/ja active Active
- 2013-08-15 PL PL13830622T patent/PL2887958T3/pl unknown
- 2013-08-21 AR ARP130102960A patent/AR092372A1/es not_active Application Discontinuation
- 2013-08-22 TW TW102130093A patent/TWI608848B/zh active
- 2013-08-22 TW TW105114326A patent/TWI683675B/zh active
2015
- 2015-02-19 MX MX2019001021A patent/MX2019001021A/es unknown
- 2015-02-20 CL CL2015000418A patent/CL2015000418A1/es unknown
2018
- 2018-05-02 JP JP2018088574A patent/JP6680827B2/ja active Active
2019
- 2019-12-12 US US16/712,261 patent/US11712419B2/en active Active
2020
- 2020-03-17 JP JP2020046303A patent/JP7098674B2/ja active Active

Also Published As

Publication number	Publication date
MX2019001021A (es)	2021-11-16
US20150224055A1 (en)	2015-08-13
MX2015002233A (es)	2015-07-06
EP2887958A4 (en)	2016-01-20
PL2887958T3 (pl)	2021-11-22
TW201412346A (zh)	2014-04-01
JP2015526467A (ja)	2015-09-10
JP6336448B2 (ja)	2018-06-06
JP6680827B2 (ja)	2020-04-15
HUE058912T2 (hu)	2022-09-28
JP2020111589A (ja)	2020-07-27
TW201642838A (zh)	2016-12-16
CA3098856C (en)	2023-10-17
JP2018150329A (ja)	2018-09-27
CN104582728A (zh)	2015-04-29
CA2879597A1 (en)	2014-02-27
RU2015107317A (ru)	2016-10-10
KR102177437B1 (ko)	2020-11-12
CA3098856A1 (en)	2014-02-27
US10548841B2 (en)	2020-02-04
KR20150042215A (ko)	2015-04-20
WO2014031429A3 (en)	2014-04-24
WO2014031429A2 (en)	2014-02-27
AR092372A1 (es)	2015-04-15
EP2887958A2 (en)	2015-07-01
RU2680096C2 (ru)	2019-02-15
JP7098674B2 (ja)	2022-07-11
MX363822B (es)	2019-04-04
CA2879597C (en)	2021-01-12
TWI683675B (zh)	2020-02-01
BR112015003658A2 (pt)	2017-07-04
ES2881671T3 (es)	2021-11-30
US20200163877A1 (en)	2020-05-28
KR20200023507A (ko)	2020-03-04
TWI608848B (zh)	2017-12-21
BR112015003658B1 (pt)	2022-09-27
EP2887958B1 (en)	2021-05-19
KR102083700B1 (ko)	2020-03-02
US11712419B2 (en)	2023-08-01

Publication	Publication Date	Title
CL2015000418A1 (es)	2015-07-10	Formulacion acuosa topica que comprende un farmaco antiangiogenico que es un anticuerpo anti-vegf y un liposoma formado de un lipido a base de peg; su uso en el tratamiento de una enfermedad o condicion relacionada con vegf; y metodo para tratar cancer, psoriasis y edema macular diabetico, entre otras enfermedades.
DOP2016000150A (es)	2016-07-15	Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
ECSP15001882A (es)	2015-09-30	Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
DOP2012000299A (es)	2013-03-31	5-fluoro-1h-pirazolopiridinas sustituidas y su uso
DOP2015000246A (es)	2015-11-15	Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CL2014000032A1 (es)	2014-08-01	Compuestos derivados de bencilamina, inhibidores de calicreina plasmatica; composicion farmaceutica; y su uso para el tratamiento de agudeza visual deteriorada, retinopatia diabetica, edema macular diabetico, hipotension cardiomiopatia, cancer, entre otros
CL2013002134A1 (es)	2013-11-29	Composicion farmaceutica oftalmica de administracion topica que comprende un androgeno; y metodo para tratar una afeccion ocular resultante de una deficiencia de androgeno.
CL2013001982A1 (es)	2014-01-10	Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad.
ECSP13012668A (es)	2013-08-30	Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
CO6710926A2 (es)	2013-07-15	Compuestos de n-heteroarilo
CL2014000050A1 (es)	2014-08-18	Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
UY35747A (es)	2015-04-30	Derivados sustituidos de fenilalanina
CL2015001187A1 (es)	2015-08-28	Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades.
CL2013003700A1 (es)	2014-07-18	Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
CL2014000267A1 (es)	2014-08-29	Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion.
DOP2016000064A (es)	2016-09-15	Derivados de fenilalanina sustituidos
UY35745A (es)	2015-04-30	Derivados sustituidos de fenilalanina
BR112013017953A2 (pt)	2017-08-29	Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
BR112015029894A2 (pt)	2017-07-25	forma de dosagem farmacêutica sólida
PE20150721A1 (es)	2015-05-23	Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion
GT201300304A (es)	2015-01-16	1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
MX2016015211A (es)	2017-06-20	Formulaciones topicas y usos de las mismas.
UY35771A (es)	2015-04-30	Tienouracil-carboxamidas cíclicas y su uso
CL2015002191A1 (es)	2016-05-20	Composición antifúngica tópica para el tratamiento de onicomicosis.
CL2014002547A1 (es)	2015-03-27	Formulacion vesicular en crema, locion, ungüento, gel, solucion, aerosol, laca o solucion filmogena, que comprende uno o mas fosfolipidos o sulfolipidos y uno o mas surfactantes; metodo para tratar la rosacea; y su uso para el tratamiento de la rosacea.